Bernstein: Melanoma mRNA vaccine advances in phase III, with initial commercial opportunity among existing PD-1 patients
An oncology expert interviewed by Bernstein believes that a personalized mRNA vaccine combined with pembrolizumab showed clinically meaningful benefit in a phase III melanoma study. However, disease stage, immunotherapy risks and the personalized manufacturing process will affect its use in practice.